drugset / Trial / NCT04247594
Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD of Voxelotor in Patients With SCD
Non-randomizedSequentialOpen-labelTreatment
Summary
Study participants will undergo up to four periods of voxelotor administered orally at progressively higher dose levels from 1500 mg until either a maximum tolerated dose (MTD) or 3000 mg/day dose is reached, whichever occurs first
Timeline
- Start
- 2020-01-09
- Primary completion
- 2021-06-08
- Completion
- 2021-06-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Voxelotor | Small molecule | 3000 mg | Oral |